|Awarded On||May 20, 2015|
|Title||GATA2 and steroid receptor coactivator-2 cooperate with androgen receptor in prostate cancer progression and androgen resistance|
|Award Mechanism||Multi-Investigator Research Awards (Version 2)|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Bert O'Malley|
Prostate Cancer (PC) is typically dependent upon androgen hormones such as testosterone that interact with the androgen receptor (AR) expressed in PC cells. Drugs designed to block AR function or block androgen synthesis in the body are currently being used in the clinic to treat PC. However, PC frequently becomes resistant to these therapeutic interventions, leading to castration-resistant prostate cancer (CRPC), a very aggressive cancer that leads to death. Importantly, CRPCs still express AR regulated genes, suggesting that the AR axis remains active. CRPC achieve resistance by promoting persistent AR axis activation in several ways such as by: 1) overexpressing cell fate-determining tran...